Published online Feb 15, 2024. doi: 10.4251/wjgo.v16.i2.458
Peer-review started: September 4, 2023
First decision: November 22, 2023
Revised: December 2, 2023
Accepted: December 20, 2023
Article in press: December 20, 2023
Published online: February 15, 2024
Processing time: 150 Days and 21.1 Hours
Gastric cancer (GC) is a prevalent malignant tumor of the gastrointestinal system. ZNF710 is a transcription factor, and ZNF710-AS1-201 is an immune-related long noncoding RNA (lncRNA) that is upregulated in GC cells.
The research is motivated by the pressing challenges posed by GC and the need for a deeper understanding of its underlying molecular mechanisms. Specifically, investigating the functional role of lncRNA ZNF710-AS1-201 and exploring the dynamics of the immune microenvironment are crucial for unraveling the complexities of GC progression. The study aims to contribute valuable insights that may have implications for precision therapy approaches in addressing this formidable disease.
The primary objectives of this research are to elucidate the functional significance of lncRNA ZNF710-AS1-201 in GC, analyze its impact on cellular processes and pathways, investigate its potential as a biomarker, and comprehensively characterize the immune microenvironment in GC tissues. By achieving these objectives, the study aims to provide a foundation for developing targeted therapeutic strategies, advancing our understanding of GC pathogenesis, and contributing to the broader field of cancer research.
This research employed a multidisciplinary approach, integrating molecular biology techniques, bioinformatics analyses, and in vitro experiments. The study involved the profiling of lncRNA ZNF710-AS1-201 expression in GC tissues, functional assays to assess its impact on cell behavior, and bioinformatics tools to unravel potential interacting pathways. Additionally, immune microenvironment analysis was conducted to explore the relationship between lncRNA expression and immune responses in GC. These methods collectively provided a comprehensive platform for investigating the role of ZNF710-AS1-201 in GC progression.
The research revealed a significant upregulation of lncRNA ZNF710-AS1-201 in GC tissues compared to adjacent normal tissues. Functional assays demonstrated that ZNF710-AS1-201 overexpression promoted cell proliferation, migration, and invasion, suggesting its potential oncogenic role. Bioinformatics analyses unveiled the involvement of ZNF710-AS1-201 in key cancer-related pathways. Moreover, immune microenvironment analysis indicated a correlation between ZNF710-AS1-201 expression and immune cell infiltration, providing insights into its potential influence on the tumor immune response in GC.
In conclusion, this study elucidates the crucial role of lncRNA ZNF710-AS1-201 in GC progression, highlighting its potential as a diagnostic and therapeutic target. The findings underscore the significance of ZNF710-AS1-201 in modulating cellular processes and its association with cancer-related pathways. Furthermore, insights into the immune microenvironment suggest its impact on the tumor immune response. Overall, these results contribute to our understanding of the molecular mechanisms underlying GC and open avenues for future research and targeted therapeutic interventions.
The study opens new perspectives for further investigation into the intricate mechanisms of lncRNA ZNF710-AS1-201 in GC. Future research should explore its potential as a biomarker for early diagnosis and prognosis. Additionally, understanding its interactions within the tumor microenvironment and elucidating its role in therapeutic resistance could pave the way for innovative treatment strategies. Collaborative efforts integrating multi-omics approaches may provide a comprehensive view of ZNF710-AS1-201’s involvement in GC, offering valuable insights for precision medicine and targeted therapies.